{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:42:06Z","timestamp":1793990526641,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2013M3A9B6046566"],"award-info":[{"award-number":["2013M3A9B6046566"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1A2B2006724"],"award-info":[{"award-number":["2018R1A2B2006724"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2015M3A9D7029882"],"award-info":[{"award-number":["2015M3A9D7029882"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1D1A1B04034638"],"award-info":[{"award-number":["2017R1D1A1B04034638"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1A5A2015385"],"award-info":[{"award-number":["2017R1A5A2015385"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gallbladder carcinoma (GBC) exhibits poor prognosis due to local recurrence, metastasis, and resistance to targeted therapies. Using clinicopathological analyses of GBC patients along with molecular in vitro and tumor in vivo analysis of GBC cells, we showed that reduction of Dsg2 expression was highly associated with higher T stage, more perineural, and lymphatic invasion. Dsg2-depleted GBC cells exhibited significantly enhanced proliferation, migration, and invasiveness in vitro and tumor growth and metastasis in vivo through Src-mediated signaling activation. Interestingly, Dsg2 binding inhibited Src activation, whereas its loss activated cSrc-mediated EGFR plasma membrane clearance and cytoplasmic localization, which was associated with acquired EGFR-targeted therapy resistance and decreased overall survival. Inhibition of Src activity by dasatinib enhanced therapeutic response to anti-EGFR therapy. Dsg2 status can help stratify predicted patient response to anti-EGFR therapy and Src inhibition could be a promising strategy to improve the clinical efficacy of EGFR-targeted therapy.<\/jats:p>","DOI":"10.1038\/s41418-020-00628-4","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T19:11:47Z","timestamp":1601320307000},"page":"968-984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation"],"prefix":"10.1038","volume":"28","author":[{"given":"Sang-Hyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Man","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Gwang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jangwook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Gil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Su","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8242-9390","authenticated-orcid":false,"given":"Hyun-Soo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Lai","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Hee","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Jun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon-Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moo-Seung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Min","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deog Yeon","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwan-Jung","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heung Jin","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang-Seong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8378-3001","authenticated-orcid":false,"given":"Hyo Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,28]]},"reference":[{"key":"628_CR1","first-page":"99","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99\u2013109.","journal-title":"Clin Epidemiol"},{"key":"628_CR2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3322\/canjclin.51.6.349","volume":"51","author":"EC Lazcano-Ponce","year":"2001","unstructured":"Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51:349\u201364.","journal-title":"CA Cancer J Clin"},{"key":"628_CR3","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/j.1572-0241.2000.02070.x","volume":"95","author":"S Sheth","year":"2000","unstructured":"Sheth S, Bedford A, Chopra S. Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. Am J Gastroenterol. 2000;95:1402\u201310.","journal-title":"Am J Gastroenterol"},{"key":"628_CR4","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","volume":"15","author":"T Andre","year":"2004","unstructured":"Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004;15:1339\u201343.","journal-title":"Ann Oncol"},{"key":"628_CR5","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S1470-2045(10)70247-3","volume":"11","author":"B Gruenberger","year":"2010","unstructured":"Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010;11:1142\u201348.","journal-title":"Lancet Oncol"},{"key":"628_CR6","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/sj.bjc.6603334","volume":"95","author":"J Harder","year":"2006","unstructured":"Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer. 2006;95:848\u201352.","journal-title":"Br J Cancer"},{"key":"628_CR7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl J Med. 2010;362:1273\u201381.","journal-title":"N. Engl J Med"},{"key":"628_CR8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","volume":"13","author":"J Lee","year":"2012","unstructured":"Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13:181\u20138.","journal-title":"Lancet Oncol"},{"key":"628_CR9","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","volume":"15","author":"D Malka","year":"2014","unstructured":"Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardiere C, Boucher E, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15:819\u201328.","journal-title":"Lancet Oncol"},{"key":"628_CR10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/onc.2010.430","volume":"30","author":"EF Dunn","year":"2011","unstructured":"Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, et al. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene. 2011;30:561\u201374.","journal-title":"Oncogene"},{"key":"628_CR11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1083\/jcb.200712133","volume":"181","author":"AE Bass-Zubek","year":"2008","unstructured":"Bass-Zubek AE, Hobbs RP, Amargo EV, Garcia NJ, Hsieh SN, Chen X, et al. Plakophilin 2: a critical scaffold for PKC alpha that regulates intercellular junction assembly. J Cell Biol. 2008;181:605\u201313.","journal-title":"J Cell Biol"},{"key":"628_CR12","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1083\/jcb.201106057","volume":"195","author":"OE Nekrasova","year":"2011","unstructured":"Nekrasova OE, Amargo EV, Smith WO, Chen J, Kreitzer GE, Green KJ. Desmosomal cadherins utilize distinct kinesins for assembly into desmosomes. J Cell Biol. 2011;195:1185\u2013203.","journal-title":"J Cell Biol"},{"key":"628_CR13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrm3802","volume":"15","author":"M Takeichi","year":"2014","unstructured":"Takeichi M. Dynamic contacts: rearranging adherens junctions to drive epithelial remodelling. Nat Rev Mol Cell Biol. 2014;15:397\u2013410.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"628_CR14","doi-asserted-by":"crossref","first-page":"37536","DOI":"10.18632\/oncotarget.7675","volume":"7","author":"AM Overmiller","year":"2016","unstructured":"Overmiller AM, McGuinn KP, Roberts BJ, Cooper F, Brennan-Crispi DM, Deguchi T, et al. c-Src\/Cav1-dependent activation of the EGFR by Dsg2. Oncotarget. 2016;7:37536\u201355.","journal-title":"Oncotarget"},{"key":"628_CR15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1600-0714.2010.00951.x","volume":"40","author":"MT Teh","year":"2011","unstructured":"Teh MT, Parkinson EK, Thurlow JK, Liu F, Fortune F, Wan H. A molecular study of desmosomes identifies a desmoglein isoform switch in head and neck squamous cell carcinoma. J Oral Pathol Med. 2011;40:67\u201376.","journal-title":"J Oral Pathol Med"},{"key":"628_CR16","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/mc.22644","volume":"56","author":"K Hutz","year":"2017","unstructured":"Hutz K, Zeiler J, Sachs L, Ormanns S, Spindler V. Loss of desmoglein 2 promotes tumorigenic behavior in pancreatic cancer cells. Mol Carcinog. 2017;56:1884\u201395.","journal-title":"Mol Carcinog"},{"key":"628_CR17","doi-asserted-by":"crossref","first-page":"e89491","DOI":"10.1371\/journal.pone.0089491","volume":"9","author":"WK Peitsch","year":"2014","unstructured":"Peitsch WK, Doerflinger Y, Fischer-Colbrie R, Huck V, Bauer AT, Utikal J, et al. Desmoglein 2 depletion leads to increased migration and upregulation of the chemoattractant secretoneurin in melanoma cells. PloS One. 2014;9:e89491.","journal-title":"PloS One"},{"key":"628_CR18","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.ejca.2006.03.024","volume":"42","author":"M Yashiro","year":"2006","unstructured":"Yashiro M, Nishioka N, Hirakawa K. Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma. Eur J Cancer. 2006;42:2397\u2013403.","journal-title":"Eur J Cancer"},{"key":"628_CR19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/pmic.201400162","volume":"15","author":"A Sirvent","year":"2015","unstructured":"Sirvent A, Urbach S, Roche S. Contribution of phosphoproteomics in understanding SRC signaling in normal and tumor cells. Proteomics. 2015;15:232\u201344.","journal-title":"Proteomics"},{"key":"628_CR20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccr.2004.09.001","volume":"6","author":"R Ishizawar","year":"2004","unstructured":"Ishizawar R, Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell. 2004;6:209\u201314.","journal-title":"Cancer Cell"},{"key":"628_CR21","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.3748\/wjg.v11.i37.5845","volume":"11","author":"U Pongchairerk","year":"2005","unstructured":"Pongchairerk U, Guan JL, Leardkamolkarn V. Focal adhesion kinase and Src phosphorylations in HGF-induced proliferation and invasion of human cholangiocarcinoma cell line HuCCA-1. World J Gastroenterol. 2005;11:5845\u201352.","journal-title":"World J Gastroenterol"},{"key":"628_CR22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/bcr55","volume":"2","author":"JS Biscardi","year":"2000","unstructured":"Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2000;2:203\u201310.","journal-title":"Breast Cancer Res"},{"key":"628_CR23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/5971","volume":"21","author":"RB Irby","year":"1999","unstructured":"Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet. 1999;21:187\u201390.","journal-title":"Nat Genet"},{"key":"628_CR24","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1054\/bjoc.2000.1560","volume":"84","author":"L Laghi","year":"2001","unstructured":"Laghi L, Bianchi P, Orbetegli O, Gennari L, Roncalli M, Malesci A. Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients. Br J Cancer. 2001;84:196\u20138.","journal-title":"Br J Cancer"},{"key":"628_CR25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0165-4608(00)00226-0","volume":"121","author":"M Nilbert","year":"2000","unstructured":"Nilbert M, Fernebro E. Lack of activating c-SRC mutations at codon 531 in rectal cancer. Cancer Genet Cytogenet. 2000;121:94\u20135.","journal-title":"Cancer Genet Cytogenet"},{"key":"628_CR26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1349-7006.2000.tb00958.x","volume":"91","author":"M Sugimura","year":"2000","unstructured":"Sugimura M, Kobayashi K, Sagae S, Nishioka Y, Ishioka S, Terasawa K, et al. Mutation of the SRC gene in endometrial carcinoma. Jpn J Cancer Res. 2000;91:395\u20138.","journal-title":"Jpn J Cancer Res"},{"key":"628_CR27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0304-3835(99)00398-5","volume":"150","author":"NM Wang","year":"2000","unstructured":"Wang NM, Yeh KT, Tsai CH, Chen SJ, Chang JG. No evidence of correlation between mutation at codon 531 of src and the risk of colon cancer in Chinese. Cancer Lett. 2000;150:201\u20134.","journal-title":"Cancer Lett"},{"key":"628_CR28","doi-asserted-by":"crossref","first-page":"32622","DOI":"10.18632\/oncotarget.5327","volume":"6","author":"JY Ahn","year":"2015","unstructured":"Ahn JY, Lee JS, Min HY, Lee HY. Acquired resistance to 5-fluorouracil via HSP90\/Src-mediated increase in thymidylate synthase expression in colon cancer. Oncotarget. 2015;6:32622\u201333.","journal-title":"Oncotarget"},{"key":"628_CR29","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/cas.12712","volume":"106","author":"Q Tan","year":"2015","unstructured":"Tan Q, Wang H, Hu Y, Hu M, Li X, Aodengqimuge, et al. Src\/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy. Cancer Sci. 2015;106:1023\u201332.","journal-title":"Cancer Sci"},{"key":"628_CR30","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.3892\/mmr.2014.2440","volume":"10","author":"K Zhang","year":"2014","unstructured":"Zhang K, Wang X, Wang H. Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549\/DDP cisplatin-resistant lung cancer cell line. Mol Med Rep. 2014;10:2065\u201372.","journal-title":"Mol Med Rep"},{"key":"628_CR31","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1083\/jcb.200809044","volume":"185","author":"S Getsios","year":"2009","unstructured":"Getsios S, Simpson CL, Kojima S, Harmon R, Sheu LJ, Dusek RL, et al. Desmoglein 1-dependent suppression of EGFR signaling promotes epidermal differentiation and morphogenesis. J Cell Biol. 2009;185:1243\u201358.","journal-title":"J Cell Biol"},{"key":"628_CR32","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1038\/onc.2013.442","volume":"33","author":"R Kamekura","year":"2014","unstructured":"Kamekura R, Kolegraff KN, Nava P, Hilgarth RS, Feng M, Parkos CA, et al. Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling. Oncogene. 2014;33:4531\u20136.","journal-title":"Oncogene"},{"key":"628_CR33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1091\/mbc.e08-04-0356","volume":"20","author":"JL Klessner","year":"2009","unstructured":"Klessner JL, Desai BV, Amargo EV, Getsios S, Green KJ. EGFR and ADAMs cooperate to regulate shedding and endocytic trafficking of the desmosomal cadherin desmoglein 2. Mol Biol Cell. 2009;20:328\u201337.","journal-title":"Mol Biol Cell"},{"key":"628_CR34","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","volume":"19","author":"CR Chong","year":"2013","unstructured":"Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19:1389\u2013400.","journal-title":"Nat Med"},{"key":"628_CR35","doi-asserted-by":"crossref","first-page":"e98786","DOI":"10.1371\/journal.pone.0098786","volume":"9","author":"AG Barber","year":"2014","unstructured":"Barber AG, Castillo-Martin M, Bonal DM, Rybicki BA, Christiano AM, Cordon-Cardo C. Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer. PloS One. 2014;9:e98786.","journal-title":"PloS One"},{"key":"628_CR36","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1096\/fj.201601138RR","volume":"31","author":"AM Overmiller","year":"2017","unstructured":"Overmiller AM, Pierluissi JA, Wermuth PJ, Sauma S, Martinez-Outschoorn U, Tuluc M, et al. Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes. FASEB J. 2017;31:3412\u201324.","journal-title":"FASEB J"},{"key":"628_CR37","doi-asserted-by":"crossref","first-page":"83060","DOI":"10.18632\/oncotarget.13067","volume":"7","author":"M Li","year":"2016","unstructured":"Li M, Chen W, Zhang H, Zhang Y, Ke F, Wu X, et al. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer. Oncotarget. 2016;7:83060\u201370.","journal-title":"Oncotarget"},{"key":"628_CR38","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00280-006-0219-4","volume":"58","author":"B Qin","year":"2006","unstructured":"Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, Harada M, et al. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Cancer Chemother Pharm. 2006;58:577\u201384.","journal-title":"Cancer Chemother Pharm"},{"key":"628_CR39","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1158\/1078-0432.CCR-12-1555","volume":"19","author":"LP Stabile","year":"2013","unstructured":"Stabile LP, He G, Lui VW, Thomas S, Henry C, Gubish CT, et al. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clin Cancer Res. 2013;19:380\u201392.","journal-title":"Clin Cancer Res"},{"key":"628_CR40","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1634\/theoncologist.2009-0009","volume":"14","author":"DL Wheeler","year":"2009","unstructured":"Wheeler DL, Iida M, Dunn EF. The role of Src in solid tumors. Oncologist. 2009;14:667\u201378.","journal-title":"Oncologist"},{"key":"628_CR41","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1158\/1535-7163.MCT-11-1020","volume":"11","author":"G Cavalloni","year":"2012","unstructured":"Cavalloni G, Peraldo-Neia C, Sarotto I, Gammaitoni L, Migliardi G, Soster M, et al. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. Mol Cancer Ther. 2012;11:1528\u201338.","journal-title":"Mol Cancer Ther"},{"key":"628_CR42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3816\/CCC.2010.n.012","volume":"9","author":"C Lieu","year":"2010","unstructured":"Lieu C, Kopetz S. The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy. Clin Colorectal Cancer. 2010;9:89\u201394.","journal-title":"Clin Colorectal Cancer"},{"key":"628_CR43","doi-asserted-by":"crossref","first-page":"8240","DOI":"10.1158\/0008-5472.CAN-07-0589","volume":"67","author":"Y Lu","year":"2007","unstructured":"Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, et al. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res. 2007;67:8240\u20137.","journal-title":"Cancer Res"},{"key":"628_CR44","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1158\/1535-7163.MCT-16-0013","volume":"15","author":"AR Nam","year":"2016","unstructured":"Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Lee KH, et al. Src as a therapeutic target in biliary tract cancer. Mol Cancer Ther. 2016;15:1515\u201324.","journal-title":"Mol Cancer Ther"},{"key":"628_CR45","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1158\/0008-5472.CAN-12-1803","volume":"73","author":"S Zhang","year":"2013","unstructured":"Zhang S, Huang WC, Zhang L, Zhang C, Lowery FJ, Ding Z, et al. SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Res. 2013;73:5764\u201374.","journal-title":"Cancer Res"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-020-00628-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-020-00628-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-020-00628-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T23:16:24Z","timestamp":1632784584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-020-00628-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["628"],"URL":"https:\/\/doi.org\/10.1038\/s41418-020-00628-4","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,28]]},"assertion":[{"value":"24 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}